Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Eltrombopag (Revolade vs Myelone) in Healthy Subjects
NCT06834451Phase 4Active, not recruiting
- Sponsor
- CAIMED
- Start
- Jun 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of eltrombopag in Thrombocytopenia, sponsored by CAIMED. Started Jun 2025; status: active, not recruiting.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT06834451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834451.